A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn?s disease - RETIC/03/06 A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Ri ...
A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn?s disease - RETIC/03/06 A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Ri ...